Chemistry:Admilparant
From HandWiki
Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.[1][2]
As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF.[2][3]
References
- ↑ "Admilparant (BMS-986278): Idiopathic Pulmonary Fibrosis Likelihood of Approval". 25 December 2023. https://www.pharmaceutical-technology.com/data-insights/admilparant-bristol-myers-squibb-idiopathic-pulmonary-fibrosis-likelihood-of-approval/.
- ↑ 2.0 2.1 "Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial". American Journal of Respiratory and Critical Care Medicine 211 (2): 230–238. October 2024. doi:10.1164/rccm.202405-0977OC. PMID 39393084.
- ↑ "Admilparant Affects Biomarkers in Pulmonary Fibrosis". 16 September 2024. https://www.medscape.com/viewarticle/admilparant-affects-biomarkers-pulmonary-fibrosis-2024a1000grd.
 |  |
